The 90 percent-plus consumers who have been vocal about wanting genetically modified organisms labeled just received a win. The MSM recently announced that the bull market is dead for biotech stocks. 
While all hyper-inflated, and propagandized stock market bubbles are not exclusive to the biotech industry, companies like Monsanto, Dow, Syngenta, and other lesser-known biotech multinationals won’t see high stock prices in the foreseeable future. The demise of the biotech bubble is being attributed to a surprising nemesis, though.
It seems, single handedly, the woman once called Frankenfood’s Bride, and a vocal supporter of GMO foods, Hillary Clinton is responsible for shrinking biotech stock prices faster than a helium balloon on a hot day. Possibly to save her campaign dreams after the public reacted extremely negatively to her outspoken support for biotech, the hopeful presidential has now tweeted outrage over ‘price gouging’ in the drug (biotech) industry.
This will make for a roller coaster we’ve seen before when stocks hit incredible highs with the Internet, and then real estate booms, only to crash doubly hard later – only this time it affects Big Pharma and Big Ag. Well, at least on the surface, to the public eye.
Between July 2010 and July 2015, the S&P 500 biotechnology index skyrocketed more than 400%. Biotech superstars like Gilead Sciences (GILD) and Regeneron (REGN) posted even more monstrous rallies.
But after Clinton’s remarks about the unbelievable price hikes by a drug maker run by Martin Shkrelli, the former hedge fund manager who’s since been dubbed the most hated man in America, even by mainstream media (MSM), is sounding alarms for biotech.
If you haven’t ditched Monsanto stock yet, it might be time. For the quarter ended Aug. 31, Monsanto reported a loss of $156 million compared with a loss of $249 million in the same period last year.
Here are 5 reasons Monsanto will continue to lose.